Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: Findings from neuroendocrine challenge tests

Psychopharmacology

Volumn 190, Issue 2, 2007, Pages 213-219

  Inoue, Y ^a   Terao, T ^b   Iwata, N ^c   Okamoto, K ^d   Kojima, H ^a   Okamoto, T ^a   Yoshimura, R ^a   Nakamura, J ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b OITA UNIVERSITY   (Japan)

^c HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^d Kokura Gamo Mental Hospital   (Japan)

Author keywords

ACTH; Cortisol; Paroxetine; PMDD; PMS

Indexed keywords

PAROXETINE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUTEAL PHASE; MENSTRUAL CYCLE; NEUROENDOCRINOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECTIVE SYMPTOMS; FEMALE; FOLLICULAR PHASE; HUMANS; HYDROCORTISONE; LUTEAL PHASE; PAROXETINE; PREMENSTRUAL SYNDROME; REFERENCE VALUES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 33845798641     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0607-9     Document Type: Article

References (21)

1. Bancroft J, Cook A (1995) The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord 36:57-64
2. Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G (1991) Blunting of neuroendocrine responses to infusion of l-tryptophan in women with perimenstrual mood change. Psychol Med 21:305-312
3. Dimmock PW, Wyatt KM, Jones PW, Shaughn O'Brien PM (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356:1131-1136
4. FitzGerald M, Malone KM, Li S, Harrison WM, McBride PA, Endicott J, Cooper T, Mann JJ (1997) Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 154:556-558
5. Freeman EW(2003) Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28:25-37
6. Freeman EW (2004) Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 18:453-468
7. Iwakawa M, Terao T, Soya A, Kojima H, Inoue Y, Ueda N, Yoshimura R, Nakamura J (2004) A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: finding from neuroendocrine challenge tests. Psychopharmacology 176(3-4):407-411
8. Kojima H, Terao T, Iwakawa M, Soya A, Inoue Y, Shiraishi Y, Son Y, Soeda S, Ueda N, Yoshimura R, Nakamura J (2003) Paroxetine as a 5-HT neuroendocrine probe. Psychopharmacology 167:97-102
9. López-Calulla C, Dominquez N (1999) Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies. J Chromatogr B 724:393-398
10. Rapkin A (2003) A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 28:39-53
11. Rasgon N, McGuire M, Tanavoli S, Fairbanks L, Rapkin A (2000) Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 73:144-149
12. Reist C, Helmeste D, Albers L, Chhay H, Tang SW (1996) Serotonin indices and impulsivity in normal volunteers. Psychiatry Res 60:177-184
13. Soya A, Terao T, Nakajima M, Kojima H, Okamoto T, Inoue Y, Iwakawa M, Shinkai K, Yoshimura R, Ueta Y, Nakamura J (2006) Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers. Psychopharmacology 187:526-527
14. Steiner M, Yatham LN, Coote M, Wilkins A, Lepage P (1999) Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res 87:107-115
15. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR (1997) Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 82:1220-1228
16. Terao T, Yoshimura R, Ohmori O, Takano T, Takahashi N, Iwata N, Suzuki T, Abe K (1997) Effect of serum cholesterol levels on meta-chlorophenylpiperazine- evoked neuroendocrine responses in healthy subjects. Biol Psychiatry 41:974-978
17. Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S, Shinkai T, Nakano H, Okuno T (2000a) Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women. Psychiatry Res 96:167-173
18. Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Shinkai T (2000b) Prediction of lithium response using m-chlorophenylpiperazine challenge test: a preliminary finding. Int Clin Psychopharmacol 15:39-42
19. Thys-Jacobs S, Alvit JMJ, Fratarcangelo P (1995) Comparative analysis of three PMS assessment instruments: the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 31:389-396
20. Veeninga AT, Westenberg HGM (1992) Serotonergic function and late luteal phase dysphoric disorder. Psychopharmacology 108:153-158
21. 1A receptor subsensitibity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can J Psychiatry 38:662-664